Lilly's next-gen drug shows significant blood sugar, weight reduction in diabetes trial

March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood sugar levels and weight in a late-stage trial, the company said on Thursday, as it looks to widen its lead in the heavily contested market for GLP-1 drugs. Drug developers are racing to enter the highly competitive and booming obesity market dominated by injectable drugs such as Novo Nordisk's